Dishman Carbogen Amcis Profit Jumps on Consolidation, Standalone Unit Struggles

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Dishman Carbogen Amcis Profit Jumps on Consolidation, Standalone Unit Struggles
Overview

Dishman Carbogen Amcis reported a significant surge in consolidated annual profit to ₹97.45 Crores, up from ₹3.24 Crores. However, the company's standalone operations saw revenue drop and losses widen to ₹38.40 Crores, with reported deviations from financial covenants.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Dishman Carbogen Amcis Reports Divergent Financial Results

Dishman Carbogen Amcis Ltd. announced its annual financial results for the year ended March 31, 2026, revealing a stark contrast between its consolidated performance and its standalone business.

Strong Consolidated Growth Masks Standalone Weakness

On a consolidated basis, the company achieved a net profit of ₹97.45 Crores, a substantial increase from ₹3.24 Crores in the previous year. Consolidated revenue also climbed 9.32% to ₹2,987.84 Crores. This overall growth suggests strength in the company's broader group operations.

However, the standalone business reported a different story. Its revenue fell to ₹316.08 Crores from ₹432.82 Crores a year prior. Net losses for the standalone entity widened considerably, reaching ₹38.40 Crores compared to ₹9.87 Crores in the prior year. Quarterly results echoed this trend, with consolidated income at ₹867.82 Crores and a profit of ₹21.74 Crores, while standalone income was ₹97.55 Crores with a net loss of ₹4.34 Crores.

Investor Concerns Rise Over Debt and Covenants

The divergence in performance is a key concern for investors. While the consolidated results show improvement, the standalone unit's struggling financials, including declining revenue and increasing losses, raise questions about its operational health. The company's overall borrowings increased to ₹2,775.40 Crores in FY26 from ₹2,083.91 Crores in FY25. Adding to these concerns, the company has reported deviations from financial covenants on its standalone borrowing arrangements.

Financing and Future Outlook

Dishman Carbogen Amcis plans to increase its borrowing limit from ₹1,700 Crores to ₹4,000 Crores, indicating a significant need for further financing. A substantial portion of existing debt, ₹2,452 Crores, is reportedly refinanced through a loan from a promoter entity, Aamanya AG. Investors will be closely monitoring the company's strategy to address the standalone business's challenges, manage its growing debt, and ensure adherence to financial covenants.

Key Metrics:

  • Consolidated Annual Revenue Growth (FY26 vs FY25): +9.32%
  • Consolidated Annual Net Profit (FY26): ₹97.45 Crores
  • Standalone Annual Revenue Change (FY26 vs FY25): -26.97%
  • Standalone Annual Net Loss (FY26): ₹38.40 Crores
  • Consolidated Borrowings (FY26): ₹2,775.40 Crores
  • Proposed Borrowing Limit: ₹4,000 Crores

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.